Service
Nuvisan is an integrated CRO from target discovery/validation to IND and further into the clinic.
Author
Watchara Sirsisko
Business Development Manager
Nuvisan ICB GmbH
Berlin, Germany
4 profile visitsRemote
Connecting innovative biotech & pharma partners with NUVISAN’s integrated discovery and development services.
My organisation
NUVISAN ICB GmbH is a Berlin-based site of the NUVISAN group, an integrated contract research organization (CRO) covering the full R&D value chain – from early discovery through preclinical development to clinical trial support. Glimpse of the Berlin Discovery Hub: We offer high-throughput screening of a proprietary 2.4M small‑molecule library, iPSC and primary cell models for translational research in oncology, CNS and women’s health, as well as biomarker discovery and multi‑omics including single‑cell, spatial and proteomics technologies. Our capabilities further include medicinal chemistry with high‑pressure reactions and chiral SFC purification, plus PK/PD and in vivo pharmacology in validated disease models. NUVISAN combines decades of pharma heritage with agile biotech culture to accelerate projects from target to patient.
About me
Business Development Manager at NUVISAN, Berlin. Background in medicinal chemistry and early drug discovery. I focus on building partnerships across pharma and biotech, from hit-to-lead to preclinical development.
Skills
- Drug discovery
- translational research
- Hit2Lead
- Screenig
- Compound Library
- Early Research
- medicinal chemistry
- In vivo
- in vitro
- ex vivo
- NGS
- sequencing
- small molecules
- Peptides
- ADC
Interests
- oncology
- women's health
- CNS Disorders
- Tranlsational Biomarkers
- High-throughput screening
Additional questions
Areas od activity
Organization type
Research organization